What is Orig3n?
Orig3n operates as a transformative force in the biotechnology sector, specializing in the democratization of genetic data and the development of personalized regenerative therapies. By providing consumers with direct, affordable access to lifestyle-related genetic insights, the company empowers proactive health management. Simultaneously, its advanced cell banking infrastructure supports commercial regenerative medicine applications, positioning Orig3n as a key player in the future of personalized healthcare. Since its 2014 inception, the firm has built one of the most comprehensive cell banks globally, bridging the gap between cutting-edge cellular science and practical medical application.
How much funding has Orig3n raised?
Orig3n has raised a total of $50.4M across 5 funding rounds:
Private Equity
$3.1M
Series A
$12.5M
Private Equity
$20M
Series B
$14.4M
Debt
$350K
Private Equity (2015): $3.1M with participation from Harris & Harris Group, KTB Network, Hatteras Venture Partners, and Mountain Group Partners
Series A (2015): $12.5M, investors not publicly disclosed
Private Equity (2017): $20M supported by 180 Degree Capital, LabCorp, Spectrum Health Ventures, KTB-KORUS Fund, MGC Venture Partners, DEFTA Partners, Hatteras Venture Partners, and Syno Capital
Series B (2018): $14.4M featuring LabCorp, Spectrum Health Ventures, 180 Degree Capital, Vectr Ventures, Mountain Group Partners, Haitong International Securities Group, DEFTA Partners, and Hatteras Venture Partners
Debt (2020): $350K backed by PPP
Key Investors in Orig3n
LabCorp
Labcorp Holdings Inc. is a global laboratory services leader providing vital diagnostic and biopharma laboratory services to support healthcare providers and patients in making informed medical decisions.
Hatteras Venture Partners
Hatteras Venture Partners is a specialized venture capital firm focused on building transformative companies within the biotech, MedTech, and HealthTech sectors.
DEFTA Partners
DEFTA Partners is a global venture investment firm that focuses on innovative technologies in healthcare and information and communication technology across North America, Asia, and Europe.
What's next for Orig3n?
Looking ahead, the recent capital injection is expected to catalyze Orig3n's expansion into more sophisticated therapeutic markets. By leveraging its extensive genetic database and proprietary cell bank, the company is well-positioned to refine its personalized medicine offerings and deepen its impact on tissue repair and disease treatment. Strategic focus will likely remain on scaling operational efficiencies and fostering partnerships within the broader healthcare ecosystem to maintain its competitive edge in the rapidly evolving biotech landscape.
See full Orig3n company page
